Vioxx GMP Violations Cited In FDA Warning Letter Spur Merck Retraining
Executive Summary
Inadequate sampling, testing, investigation and documentation of Merck's Vioxx (rofecoxib) lots are among good manufacturing practice violations cited in a June 27 FDA warning letter.